Kamori et al. (2021) reported that CRC with ARID1A variations was likely to have a higher tumor mutational burden, while ARID1A-deficient CRC was frequently accompanied by enhanced PD-L1 expression by stromal cells. Here, ARID1A is linked to neoplasm.